CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The product is expected to be available in early August.
The FDA has given its approval to Suflave™, an osmotic laxative designed for colon cleansing prior to colonoscopy in adults. This marks a significant step in providing a low-volume preparation method with taste likened to a sports drink. The approval was rooted in robust clinical trials, focusing on efficacy and safety, leading to a promising alternative in colonoscopy preparation.
Key Points:
- Suflave, containing polyethylene glycol 3350 and various electrolytes, has been approved by the FDA as a colonoscopy preparation for adults.
- Two randomized, single-blind, active-controlled trials (Study 1 and Study 2) were the basis of the approval, with ClinicalTrials.gov Identifiers NCT04446299 and NCT04446312.
- 93% (Study 1) and 94% (Study 2) of patients receiving Suflave achieved successful bowel preparation, as rated by blinded endoscopists, compared with 89% and 94% for active comparators.
Additional Points:
- Suflave will be supplied in cartons containing 2 bottles and 2 lemon-lime flavor enhancing packets.
Conclusion:
- Suflave’s approval, reflecting a strong performance in clinical trials, brings a new, efficient option for colonoscopy preparation that emphasizes patient choice and improves the taste experience.
Gastroenterology Latest Posts
- What is ‘Fried Rice Syndrome,’ and Why is it Killing People?
- Recognizing the 25 Indicators of Pancreatic Cancer
- How Might Drinking Coffee Alter Your Gut Microbiome?
- Ohio Jury Awards Over $2 Million to Family of Woman Who Died Following Common Surgery
“We believe in patient choice and are committed to improving the colon preparation process for patients. We are delighted with the FDA’s approval of Suflave – which has efficacy equivalent to Suprep, but with taste similar to a sports drink.”
Alan Cooke
President and CEO
Sebela Pharmaceuticals
